- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J Med Virol. 2019 Oct 14. doi: 10.1002/jmv.25608. [Epub ahead of print]
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH1, Liao J1, Zhang DM1, Wu DB1, Tao YC1, Wang ML1, Chen EQ1, Tang H1.
Author information
1
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Abstract
AIMS:
The aim of this retrospective study was to compare the efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy and TDF+entecavir (ETV) combination therapy for chronic hepatitis B (CHB) patients with partial virological response (PVR) to ETV.
METHODS:
CHB patients with PVR to ETV were switched to TDF monotherapy or TDF+ETV combination therapy. The primary efficacy outcome was virological response(VR), and the secondary efficacy outcomes were HBeAg seroconversion and ALT normalization. The primary safety outcomes were changes in serum creatinine and serum phosphorus levels.
RESULTS:
A total of 143 patients were investigated, including 63 patients in TDF monotherapy group and 80 patients in TDF+ETV combination therapy group. Baseline demographics and clinical characteristics were comparable between groups. The median age of patients was 44.5 years, and 76.2% of them were male. The VR rate in TDF+ETV group was higher than that of TDF group at 48 weeks (88.8% vs 71.4%; P=0.009). At 48 weeks, HBeAg seroconversion rate of TDF+ETV group was higher than that of TDF group (30% vs 15.9%; P=0.049). There was no significant difference in the proportion of patients with elevated ALT in TDF group and TDF+ETV group at 48 weeks (9.5% vs 7.5%, P=0.665). After adjusting the treatment regimen, serum creatinine level increased slightly and serum phosphorus level decreased slightly in both groups.
CONCLUSIONS:
TDF+ETV combination therapy for 48 weeks had higher virological response rate than TDF monotherapy in CHB patients with partial virological response to ETV. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
antiviral therapy; chronic hepatitis B; combination therapy; entecavir; partial virologic response; tenofovir
PMID:
31609007
DOI:
10.1002/jmv.25608
|
|